MX9203346A - (+)-1-(3-dimetilaminopropil)-1-(4'-fluorfenil)-1,3-dihidro-sobenofuran -5-carbonitrilo y sus sales de adicion de acido no toxicas farmaceuticamente utiles. - Google Patents

(+)-1-(3-dimetilaminopropil)-1-(4'-fluorfenil)-1,3-dihidro-sobenofuran -5-carbonitrilo y sus sales de adicion de acido no toxicas farmaceuticamente utiles.

Info

Publication number
MX9203346A
MX9203346A MX9203346A MX9203346A MX9203346A MX 9203346 A MX9203346 A MX 9203346A MX 9203346 A MX9203346 A MX 9203346A MX 9203346 A MX9203346 A MX 9203346A MX 9203346 A MX9203346 A MX 9203346A
Authority
MX
Mexico
Prior art keywords
sobenofuran
dimetilaminopropil
fluorfenil
carbonitrilo
dihidro
Prior art date
Application number
MX9203346A
Other languages
English (en)
Inventor
Klaus Peter Bogeso
Jens Kristian Perregaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10638616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9203346(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX9203346A publication Critical patent/MX9203346A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Silicon Compounds (AREA)
MX9203346A 1988-06-14 1992-06-25 (+)-1-(3-dimetilaminopropil)-1-(4'-fluorfenil)-1,3-dihidro-sobenofuran -5-carbonitrilo y sus sales de adicion de acido no toxicas farmaceuticamente utiles. MX9203346A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888814057A GB8814057D0 (en) 1988-06-14 1988-06-14 New enantiomers & their isolation
US07/363,589 US4943590A (en) 1988-06-14 1989-06-08 Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydrosobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof

Publications (1)

Publication Number Publication Date
MX9203346A true MX9203346A (es) 1992-08-31

Family

ID=10638616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203346A MX9203346A (es) 1988-06-14 1992-06-25 (+)-1-(3-dimetilaminopropil)-1-(4'-fluorfenil)-1,3-dihidro-sobenofuran -5-carbonitrilo y sus sales de adicion de acido no toxicas farmaceuticamente utiles.

Country Status (24)

Country Link
US (2) US4943590A (es)
EP (1) EP0347066B1 (es)
JP (2) JP3044253B2 (es)
AT (1) ATE119896T1 (es)
AU (1) AU623144B2 (es)
CA (2) CA1339452C (es)
CY (2) CY2081B1 (es)
DE (2) DE68921672T2 (es)
DK (2) DK259989A (es)
ES (1) ES2068891T4 (es)
FI (4) FI98627C (es)
GB (1) GB8814057D0 (es)
GR (1) GR3015889T3 (es)
HK (1) HK139596A (es)
HU (1) HU211460A9 (es)
IE (1) IE65734B1 (es)
IL (1) IL90465A (es)
LU (1) LU90999I2 (es)
MX (1) MX9203346A (es)
NL (1) NL300155I2 (es)
NO (2) NO172892C (es)
NZ (1) NZ229426A (es)
PT (1) PT90845B (es)
ZA (1) ZA894476B (es)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322851A (en) * 1990-07-02 1994-06-21 H. Lundbeck A/S Indole derivatives
US5665270A (en) * 1991-05-20 1997-09-09 Chisso Corporation Optically active trifluorolactic acid derivative and liquid crystal composition
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
DE4439836C1 (de) * 1994-11-08 1996-06-05 Hoechst Ag cis-4-(2,2,3,3-Tetrafluorpropoxy)-zimtsäurenitril und trans-4-(2,2,3,3-Tetrafluorpropoxy)- zimtsäurenitril und ein Verfahren zu ihrer Herstellung
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
PL199423B1 (pl) * 1998-10-20 2008-09-30 Lundbeck & Co As H Sposób wytwarzania citalopramu
PT1140886E (pt) 1998-12-23 2003-08-29 Lundbeck & Co As H Metodo para a preparacao de 5- cianoftalida
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
BR9917346A (pt) * 1999-04-14 2002-02-26 Lundbeck & Co As H Método para preparação de citalopram intermadiário e utilização do mesmo
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6759437B2 (en) 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
ATE277032T1 (de) * 1999-10-25 2004-10-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
GB2360281B (en) * 1999-10-25 2002-01-16 Lundbeck & Co As H Method for the preparation of citalopram
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
MXPA02006503A (es) 1999-12-28 2002-12-09 Lundbeck & Co As H Metodo para la preparacion de citalopram.
CA2397270C (en) * 2000-01-14 2007-08-21 H. Lundbeck A/S Method for the preparation of 5-cyanophthalide
FR2805812A1 (fr) 2000-02-24 2001-09-07 Lundbeck & Co As H Procede de preparation du citalopram
IES20010157A2 (en) * 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
NZ521201A (en) * 2000-03-13 2004-02-27 H Method for the preparation of citalopram
TR200202195T2 (tr) * 2000-03-13 2002-12-23 H. Lundbeck A/S 5-Yer değiştirmiş 1-(4-florofenil)-1,3- dihidroizobenzofuran'ın adım adım alkillenmesi
IES20010206A2 (en) 2000-03-13 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
CN1418205A (zh) 2000-03-14 2003-05-14 H·隆德贝克有限公司 制备西酞普兰的方法
IL151487A0 (en) * 2000-03-16 2003-04-10 Lundbeck & Co As H Method for the preparation of 5-cyano-1-(4-flourophenyl)-1,3-dihydroisobenzofurans
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
EA008373B1 (ru) * 2000-07-07 2007-04-27 Х. Лундбекк А/С Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
EA008372B1 (ru) * 2000-07-07 2007-04-27 Х.Лундбекк А/С Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой
AU7090201A (en) * 2000-07-20 2002-02-05 Lauras As Method
CA2353693C (en) * 2000-08-10 2003-07-22 H. Lundbeck A/S Pharmaceutical composition containing citalopram
IL144816A (en) 2000-08-18 2005-09-25 Lundbeck & Co As H Method for the preparation of citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
CN1366526A (zh) * 2000-12-28 2002-08-28 H·隆德贝克有限公司 纯西酞普兰的制备方法
CA2435925A1 (en) 2001-01-30 2002-08-08 Orion Corporation Fermion Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
EP1385503A1 (en) * 2001-05-01 2004-02-04 H. Lundbeck A/S The use of enantiomeric pure escitalopram
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
DK1522539T3 (da) * 2001-07-31 2007-05-07 Lundbeck & Co As H Krystallinsk komposition indeholdende excitalopram
ES2234797T3 (es) * 2001-08-02 2005-07-01 Infosint Sa Procedimiento para la preparacion de citalopram partiendo de 5-formilftalida.
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
AU2003222435A1 (en) * 2002-01-07 2003-07-24 Sun Pharmaceutical Industries Limited Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
AU2003207774A1 (en) * 2002-01-30 2003-09-02 Montana State University Pestalotiopsis microsporia isolates and compounds derived therefrom
EP1346989A1 (en) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Improved process for the preparation of citalopram and its hydrobromide
CA2381341A1 (en) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Process and intermediates for preparing escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
PE20040991A1 (es) * 2002-08-12 2004-12-27 Lundbeck & Co As H Separacion de intermediarios para la preparacion de escitalopram
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
EP2363389A1 (en) 2002-12-23 2011-09-07 H. Lundbeck A/S A process for the preparation of racemic citalopram diol and/or S- or R-citalopram diols and the use of such diols for the preparation of racemic citalopram, R-citalopram and/or S-citalopram
ES2298595T3 (es) * 2002-12-23 2008-05-16 H. Lundbeck A/S Hidrobromuro de escitalopram y un metodo para su preparacion.
TWI331605B (en) * 2002-12-23 2010-10-11 Lundbeck & Co As H A process for the preparation of racemic citalopram diol and/or s- or r-citalopram diols and the use of such diols for the preparation of racemic citalopram, r-citalopram and/or s-citalopram
CA2519629A1 (en) * 2003-03-21 2004-09-30 H. Lundbeck A/S Intermediates for the preparation of citalopram and escitalopram
TR200504022T1 (tr) * 2003-03-24 2006-08-21 Hetero Drugs Limited (S)-sitalopram oksalatın yeni sıvı kristal formları.
EP1486492A3 (en) 2003-06-10 2005-02-23 Sun Pharmaceuticals Industries Ltd. A process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran.
RU2320369C2 (ru) 2003-09-12 2008-03-27 Пфайзер Инк. Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина
ES2228274B1 (es) * 2003-09-24 2006-06-01 Astur Pharma, S.A. Sintesis quimioenzimatica de (+)-citalopram y (-)-citalopram.
DK1506963T3 (da) * 2003-10-28 2005-08-01 Adorkem Technology Spa Fremgangsmåde til fremstilling af citalopram
US20050101666A1 (en) * 2003-11-07 2005-05-12 H. Lundbeck A/S Method of treating premenstrual dysphoric disorder with escitalopram
EP1706394B1 (en) * 2003-11-12 2014-12-17 Dr. Reddy's Laboratories, Inc. Preparation of escitalopram
US20050107466A1 (en) * 2003-11-17 2005-05-19 H. Lundbeck A/S Method of treating or reducing suicidal thoughts with escitalopram
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
AU2003282383A1 (en) * 2003-11-20 2005-06-08 Natco Pharma Limited A process for the preparation of high purity escitalopram
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
NZ549100A (en) * 2004-03-05 2010-02-26 Lundbeck & Co As H Crystalline composition containing escitalopram oxalate
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
ITMI20040717A1 (it) 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
ES2285972T1 (es) 2004-08-23 2007-12-01 Sun Pharmaceutical Industries Limited Procedimiento de fabricacion de citalopram y enantiomeros.
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
WO2006025071A1 (en) * 2004-09-02 2006-03-09 Natco Pharma Limited A process for the preparation of escitalopram
ITMI20041872A1 (it) 2004-10-01 2005-01-01 Adorkem Technology Spa Processo per la preparazione di citalopram e di scitalopram
WO2006106531A1 (en) * 2005-04-04 2006-10-12 Jubilant Organosys Ltd Process for the preparation of escitalopram or its acid addition salts
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
CA2604916A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
WO2006116165A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
WO2006116170A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AU2006239922A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists
ITTO20050301A1 (it) * 2005-05-05 2006-11-06 Errekappa Euroterapici Spa Formulazioni liquide orali contenenti citalopram
WO2006123243A2 (en) * 2005-05-20 2006-11-23 Aurobindo Pharma Limited Pharmaceutical dosage forms comprising escitalopram in form of granules
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US7939680B2 (en) * 2005-07-27 2011-05-10 Aurobindo Pharma Ltd. Process for the preparation of Escitalopram
WO2007048080A2 (en) * 2005-10-14 2007-04-26 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
US7569605B2 (en) * 2005-10-14 2009-08-04 Forest Laboratories Holdings Limited Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
JP2009515840A (ja) * 2005-11-14 2009-04-16 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムの製造方法
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200806300A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment of depression
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
EP2086509A1 (en) * 2006-10-20 2009-08-12 Ratiopharm GmbH Escitalopram and solid pharmaceutical composition comprising the same
WO2008050673A1 (fr) 2006-10-27 2008-05-02 Hisamitsu Pharmaceutical Co., Inc. Timbre transdermique adhésif
US20080153825A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
US20080153927A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153881A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153880A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153808A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20080153832A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
WO2008104880A2 (en) * 2007-03-01 2008-09-04 Aurobindo Pharma Limited Stable solid dosage forms of an antidepressant
US7566793B2 (en) * 2007-04-23 2009-07-28 Synthon Bv Process for resolving citalopram
WO2008142379A2 (en) 2007-05-18 2008-11-27 Cipla Limited Process for the preparation of escitalopram via desmethylcitalopram, optical resolution and methylation of the s-isomer
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
AU2008283989B2 (en) * 2007-08-03 2013-12-05 Richter Gedeon Nyrt. Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands.
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
US8022232B2 (en) 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
NZ570884A (en) 2007-09-11 2010-03-26 Lundbeck & Co As H Fractionally crystallising 4-[4-(dimethyl amino)-1-(4'-fluorophenyl)-1-hydroxybutyI]-3-(hydroxymethyl)-benzonitrile and manufacturing escitalopram therefrom
US9339500B2 (en) * 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
CN101538257B (zh) * 2008-03-21 2012-10-17 浙江华海药业股份有限公司 一种制备西酞普兰和s-西酞普兰的方法
CN101265215B (zh) * 2008-04-18 2011-03-16 浙江奥托康制药集团股份有限公司 一种右旋西酞普兰中间体s-型二醇的制备方法
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
US20110230666A1 (en) * 2008-06-03 2011-09-22 Shodhana Laboratories Limited process for the separation of enantiomerically pure compounds
US20110092719A1 (en) * 2008-06-16 2011-04-21 Shodhana Laboratories Limited Preparation of Escitalopram, Its Salts and Intermediates
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤
US20100249438A1 (en) * 2009-03-30 2010-09-30 Vijaya Bhaskar Bolugoddu Preparation of escitalopram
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
CN102190600B (zh) * 2010-03-13 2015-04-15 浙江华海药业股份有限公司 一种右旋西酞普兰中间体s-型二醇的制备方法
CN102757414B (zh) * 2011-04-25 2014-02-19 齐鲁制药有限公司 艾司西酞普兰草酸盐的制备方法
WO2013081567A1 (en) 2011-12-02 2013-06-06 Mahmut Bilgic Effervescent antipsychotic formulations
WO2013100870A1 (en) 2011-12-02 2013-07-04 Mahmut Bilgic New antipsychotic compositions
ITMI20120105A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Soluzione acquosa di escitalopram ossalato e relativo utilizzo
ITMI20120448A1 (it) 2012-01-30 2013-07-31 Carthesia Sas Composizione liofilizzata di escitalopram ossalato per somministrazione sublinguale
CN104119248A (zh) * 2014-08-08 2014-10-29 广东东阳光药业有限公司 S-西酞普兰的制备方法
WO2016074225A1 (zh) * 2014-11-14 2016-05-19 浙江华海药业股份有限公司 一种拆分西酞普兰中间体5-氰二醇的方法
EP3309142B1 (en) 2015-06-09 2020-08-05 Zhejiang Huahai Pharmaceutical Co., Ltd Method for preparing citalopram diol intermediate
CN107311968A (zh) * 2016-03-31 2017-11-03 广州市恒诺康医药科技有限公司 西酞普兰帕莫酸盐和其结晶形态及其制备方法和用途
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
EP3694843B1 (en) 2017-10-09 2022-01-26 Hasleton, Mark New salt and solid state forms of escitalopram
CN111217777A (zh) 2018-11-26 2020-06-02 上海奥博生物医药技术有限公司 一种高纯度艾司西酞普兰双羟萘酸盐新的制备工艺
JP2022540706A (ja) 2019-07-19 2022-09-16 バイオエクセル セラピューティクス，インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
KR102441089B1 (ko) 2020-06-15 2022-09-07 환인제약 주식회사 의약 조성물
WO2022153262A1 (en) 2021-01-18 2022-07-21 Anton Frenkel Pharmaceutical dosage form
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method

Also Published As

Publication number Publication date
AU623144B2 (en) 1992-05-07
AU623144C (en) 1990-01-04
FI20000507A (fi) 2000-03-06
NZ229426A (en) 1990-12-21
NO892447D0 (no) 1989-06-13
JP3038204B2 (ja) 2000-05-08
ES2068891T3 (es) 1995-05-01
NO892447L (no) 1989-12-15
DK11593A (da) 1993-02-01
CY2081B1 (en) 1998-10-16
ES2068891T4 (es) 2012-02-07
DE68921672T2 (de) 1995-07-27
FI892823A0 (fi) 1989-06-08
NO172892B (no) 1993-06-14
EP0347066B1 (en) 1995-03-15
DE10399030I2 (de) 2004-08-12
DK259989D0 (da) 1989-05-29
IE65734B1 (en) 1995-11-15
IL90465A (en) 1995-01-24
NO172892C (no) 1993-09-22
CY2007004I2 (el) 2009-11-04
CA1339568C (en) 1997-12-02
DK170280B1 (da) 1995-07-24
JPH11292867A (ja) 1999-10-26
CY2007004I1 (el) 2009-11-04
JPH0236177A (ja) 1990-02-06
USRE34712E (en) 1994-08-30
CA1339452C (en) 1997-09-09
FI113762B1 (fi) 2004-06-15
PT90845B (pt) 1994-11-30
US4943590A (en) 1990-07-24
ATE119896T1 (de) 1995-04-15
FI91527B (fi) 1994-03-31
FI20041359A (fi) 2004-10-20
GR3015889T3 (en) 1995-07-31
FI941829A (fi) 1994-04-20
FI941829A0 (fi) 1994-04-20
PT90845A (pt) 1989-12-29
NO2002014I2 (no) 2005-03-21
EP0347066A1 (en) 1989-12-20
NL300155I2 (nl) 2005-09-01
DK11593D0 (da) 1993-02-01
DE68921672D1 (de) 1995-04-20
FI98627C (fi) 1997-07-25
LU90999I2 (fr) 2003-03-17
HU211460A9 (en) 1995-11-28
JP3044253B2 (ja) 2000-05-22
AU3629589A (en) 1990-01-04
DE10399030I1 (de) 2004-01-08
GB8814057D0 (en) 1988-07-20
HK139596A (en) 1996-08-02
IE891859L (en) 1989-12-14
ZA894476B (en) 1990-04-25
FI892823A (fi) 1989-12-15
NL300155I1 (nl) 2004-09-01
DK259989A (da) 1989-12-15

Similar Documents

Publication Publication Date Title
MX9203346A (es) (+)-1-(3-dimetilaminopropil)-1-(4'-fluorfenil)-1,3-dihidro-sobenofuran -5-carbonitrilo y sus sales de adicion de acido no toxicas farmaceuticamente utiles.
DE69201959D1 (de) Verfahren zur Herstellung von 6,12-Dihydro-6-hydroxy-cannabidiol und dessen Anwendung zur Herstellung von trans-delta-9-Tetrahydrocannabinol.
DK89595A (da) Fremgangsmåde til fremstilling af 1-(3-dimethylaminopropyl)-1'-(4-fluorphenyl)-1,3-dihydroisobenzofuran-5-carbonnitril
ATE132145T1 (de) Verfahren zur herstellung von bacchatin iii und von desacetyl-10-bacchatin iii derivate
ATE159512T1 (de) Prozess zur herstellung von beta-phenylisoserin und analogen verbindungen
ATE207482T1 (de) Verfahren zur herstellung von n2-arylsulfonyl-l- argininamiden
ATE159246T1 (de) Verfahren zur herstellung von (s)-vinyl- und (s)- allenyl-gaba
IT8621359A1 (it) Processo per la sintesi di acidi carbossilici
ATE117676T1 (de) Verfahren zur herstellung von molluskiziden 2,4,5-tribrompyrrol-3-carbonitrilen.
ATE157655T1 (de) Verfahren zur herstellung von gegebenfalls 2- substituierten 5-chlorimidazolen
ATE111093T1 (de) Verfahren zur herstellung von enantiomeren von 3- aminchromanderivaten.
DE68905799D1 (de) (+)1-((3,4,5-trimethoxy)benzyloxymethyl)-1-phenyl-n,n-dimethyl-n-propylamine, verfahren zu ihrer herstellung und ihre therapeutische verwendung.
FI875602A0 (fi) Optiskt aktivt tetrahydro-2-furanonderivat saosom miksobicid.
ATE35679T1 (de) Verfahren zur herstellung von cis-3,3,5trimethylcyclohexyl-d,l-alpha-(3-pyridincarboxy - phenylacetat.